Please enter the email address you used to register, then we will send you a link to choose a new password
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004...
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of...
UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $1.2 to $1.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers t...
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate ...
Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, ev...